← Back to Search

Mesenchymal Stromal Cells

Allogeneic Wharton's jelly-MSCs (WJ-MSC) for Coronavirus (ProTrans19+ Trial)

Phase 2
Waitlist Available
Led By Ines Colmegna
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7, 15 and 30
Awards & highlights

ProTrans19+ Trial Summary

This trial tests if a treatment using stem cells can help treat COVID, alongside standard care.

Eligible Conditions
  • Coronavirus

ProTrans19+ Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrolment to discharge or icu transfer or death
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrolment to discharge or icu transfer or death for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite endpoint
Secondary outcome measures
Clinical status evaluation assessed by the 9-point ordinal scale
Duration of hospitalization and ICU stay
Survival
+1 more

ProTrans19+ Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Allogeneic Wharton's jelly-MSCs (WJ-MSC)Experimental Treatment1 Intervention
Intravenous administration, 1 dose, for 20 minutes
Group II: PlaceboPlacebo Group1 Intervention
Intravenous administration, 1 dose, for 20 minutes

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
159,155 Total Patients Enrolled
Ines ColmegnaPrincipal InvestigatorResearch Institute of the McGill University Health Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells
Ines Colmegna 2021. "Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04869397.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top